[41] Pérez-Molina JA, Sojo-

Dorado J, Norman F, Monge-Maillo B, Díaz-Menéndez M, Albajar-Viñas P, et al. Nifurtimox therapy for Chagas disease does not cause hypersensitivity reactions in patients with such previous adverse reactions during benznidazole treatment. Acta Tropica. 2013;**127**(2):101-104

[42] Pérez-Molina JA, Molina I. Chagas disease. Lancet. 2018;**391**(10115):82-94

[43] Viotti R, Vigliano C, Armenti H, Segura E. Treatment of chronic Chagas' disease with benznidazole: Clinical and

serologic evolution of patients with longterm follow-up. American Heart Journal. 1994;**127**(1):151-162

[44] Hasslocher-Moreno AM, Saraiva RM, Sangenis LHC, Xavier SS, de Sousa AS, Costa AR, et al. Benznidazole decreases the risk of chronic Chagas disease progression and cardiovascular events: A long-term follow up study. eClinicalMedicine. 2021;**31**:100694

[45] Urbina JA. Parasitological cure of Chagas disease: Is it possible? Is it relevant? Memórias do Instituto Oswaldo Cruz. 1999;**94**(Suppl. 1):349-355

[46] Cal M, Ioset J-R, Fügi MA, Mäser P, Kaiser M. Assessing anti-*T. cruzi* candidates in vitro for sterile cidality. International Journal for Parasitology: Drugs and Drug Resistance. 2016;**6**(3):165-170

[47] Neal RA, van Bueren J. Comparative studies of drug susceptibility of five strains of *Trypanosoma cruzi* in vivo and in vitro. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1988;**82**(5):709-714

[48] Lin C, Ferreira de Almeida Fiuza L, Cardoso Santos C, Ferreira Nunes D, Cruz Moreira O, Bouton J, et al. 6-Methyl-7-aryl-7-deazapurine nucleosides as anti-*Trypanosoma cruzi* agents: Structure-activity relationship and in vivo efficacy. ChemMedChem. 2021;**16**(14):2231-2253

[49] Pinazo M-J, Espinosa G, Cortes-Lletget C, Posada E, Aldasoro E, Oliveira I, et al. Immunosuppression and Chagas disease: A management challenge. PLoS Neglected Tropical Diseases. 2013;**7**(1):e1965

[50] Sánchez-Valdéz FJ, Padilla A, Wang W, Orr D, Tarleton RL. Spontaneous dormancy protects *Trypanosoma cruzi* during

extended drug exposure. eLife. 2018;**26**(7):e34039

[51] Barrett MP, Kyle DE, Sibley LD, Radke JB, Tarleton RL. Protozoan persister-like cells and drug treatment failure. Nature Reviews. Microbiology. 2019;**17**(10):607-620

[52] Nagajyothi F, Machado FS, Burleigh BA, Jelicks LA, Scherer PE, Mukherjee S, et al. Mechanisms of *Trypanosoma cruzi* persistence in Chagas disease. Cellular Microbiology. 2012;**14**(5):634-643

[53] Strömme JH. Effects of diethyldithiocarbamate and disulfiram on glucose metabolism and glutathione content of human erythrocytes. Biochemical Pharmacology. 1963;**12**(7):705-715

[54] Mittal M, Khan K, Pal S, Porwal K, China SP, Barbhuyan TK, et al. The thiocarbamate disulphide drug, disulfiram induces osteopenia in rats by inhibition of osteoblast function due to suppression of acetaldehyde dehydrogenase activity. Toxicological Sciences. 2014;**139**(1):257-270

[55] Heikkila RE, Cabbat FS, Cohen G. Inactivation of superoxide dismutase by several thiocarbamic acid derivatives. Experientia. 1978;**34**(12):1553-1554

[56] Heikkila RE, Cabbat FS, Cohen G. In vivo inhibition of superoxide dismutase in mice by diethyldithiocarbamate. The Journal of Biological Chemistry. 1976;**251**(7):2182-2185

[57] Doyon G, Zerbato J, Mellors JW, Sluis-Cremer N. Disulfiram reactivates latent HIV-1 expression through depletion of the phosphatase and tensin homolog. AIDS. 2013;**27**(2):F7-F11

[58] Kim Y, Anderson JL, Lewin SR. Getting the "Kill" into "Shock and Kill": *Translational Research on Chagas Disease: Focusing on Drug Combination and Repositioning DOI: http://dx.doi.org/10.5772/intechopen.104231*

Strategies to eliminate latent HIV. Cell Host & Microbe. 2018;**23**(1):14-26

[59] Maeda FY, Cortez C, Yoshida N. Cell signaling during *Trypanosoma cruzi* invasion. Frontiers in Immunology. 2012;**3**:361

[60] Burleigh BA, Woolsey AM. Cell signalling and *Trypanosoma cruzi* invasion. Cellular Microbiology. 2002;**4**(11):701-711

[61] Chuenkova MV, Furnari FB, Cavenee WK, Pereira MA. *Trypanosoma cruzi* trans-sialidase: A potent and specific survival factor for human Schwann cells by means of phosphatidylinositol 3-kinase/ Akt signaling. Proceedings of the National Academy of Sciences. 2001;**98**(17):9936-9941

[62] Zhang H, Chen D, Ringler J, Chen W, Cui QC, Ethier SP, et al. Disulfiram treatment facilitates phosphoinositide 3-kinase inhibition in human breast cancer cells in vitro and in vivo. Cancer Research. 2010;**70**(10):3996-4004

[63] Bustamante JM, Sanchez-Valdez F, Padilla AM, White B, Wang W, Tarleton RL. A modified drug regimen clears active and dormant trypanosomes in mouse models of Chagas disease. Science Translational Medicine. 2020;**12**(567):eabb7656

[64] Pessenda G, Silva JS. Arginase and its mechanisms in Leishmania persistence. Parasite Immunology. 2020;**42**(7):e12722

[65] Mejia AM, Hall BS, Taylor MC, Gómez-Palacio A, Wilkinson SR, Triana-Chávez O, et al. Benznidazoleresistance in *Trypanosoma cruzi* is a readily acquired trait that can arise independently in a single population. The Journal of Infectious Diseases. 2012;**206**(2):220-228

[66] Campos MCO, Leon LL, Taylor MC, Kelly JM. Benznidazole-resistance in *Trypanosoma cruzi*: Evidence that distinct mechanisms can act in concert. Molecular and Biochemical Parasitology. 2014;**193**(1):17-19

[67] Francisco AF, Jayawardhana S, Olmo F, Lewis MD, Wilkinson SR, Taylor MC, et al. Challenges in Chagas disease drug development. Molecules. 2020;**25**(12):2799

[68] Filardi LS, Brener Z. Susceptibility and natural resistance of *Trypanosoma cruzi* strains to drugs used clinically in Chagas disease. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1987;**81**(5):755-759

[69] Zingales B. *Trypanosoma cruzi* genetic diversity: Something new for something known about Chagas disease manifestations, serodiagnosis and drug sensitivity. Acta Tropica. 2018; **184**:38-52

[70] Teston APM, Monteiro WM, Reis D, Bossolani GDP, Gomes ML, de Araújo SM, et al. In vivo susceptibility to benznidazole of *Trypanosoma cruzi* strains from the western Brazilian Amazon. Tropical Medicine & International Health. 2013;**18**(1):85-95

[71] Zingales B, Araujo RGA, Moreno M, Franco J, Aguiar PHN, Nunes SL, et al. A novel ABCG-like transporter of *Trypanosoma cruzi* is involved in natural resistance to benznidazole. Memórias do Instituto Oswaldo Cruz. 2015;**110**(3):433-444

[72] Loffredo L, Violi F. COVID-19 and cardiovascular injury: A role for oxidative stress and antioxidant treatment? International Journal of Cardiology. 2020;**312**:136

[73] Dichi I, Breganó JW, Simão ANC, Cecchini R. Role of Oxidative Stress in Chronic Diseases. 1st ed. Boca Raton: CRC Press; 2014. 720 p

[74] Bondy SC, Campbell A. Inflammation, aging, and oxidative stress. In: Bondy SC, Campbell A, editors. Oxidative Stress in Applied Basic Research and Clinical Practice. Cham: Springer International Publishing; 2016

[75] Armstrong D, Stratton RD. Oxidative Stress and Antioxidant Protection: The Science of Free Radical Biology and Disease. 1st ed. Hoboken, New Jersey: John Wiley & Sons Inc.; 2016. 600 p

[76] Sies H. (Ed.). Oxidative stress: eustress and distress. London: Academic Press; 2020. 829 p

[77] Lushchak V, Semchyshyn H, editors. Oxidative Stress: Molecular Mechanisms and Biological Effects. London, UK: InTechOpen; 2012

[78] Flohé L. Glutathione. Boca Raton: Taylor & Francis; 2018

[79] Piñeyro MD, Arias D, Parodi-Talice A, Guerrero S, Robello C. Trypanothione metabolism as drug target for trypanosomatids. Current Pharmaceutical Design. 2021;**27**(15): 1834-1846

[80] Fairlamb AH, Cerami A. Metabolism and functions of trypanothione in the kinetoplastida. Annual Review of Microbiology. 1992;**46**(1):695-729

[81] Pountain AW, Weidt SK, Regnault C, Bates PA, Donachie AM, Dickens NJ, et al. Genomic instability at the locus of sterol C24-methyltransferase promotes amphotericin B resistance in Leishmania parasites. PLoS Neglected Tropical Diseases. 2019;**13**(2):e0007052

[82] Ozols RF, O'Dwyer PJ, Hamilton TC, Young RC. The role of glutathione in

drug resistance. Cancer Treatment Reviews. 1990;**17**:45-50

[83] Schröder CP, Godwin AK, O'Dwyer PJ, Tew KD, Hamilton TC, Ozols RF. Glutathione and drug resistance. Cancer Investigation. 1996;**14**(2):158-168

[84] Russell TM, Azad MG, Richardson DR. The relationship of glutathione-S-transferase and multidrug resistance-related protein 1 in nitric oxide (NO) transport and storage. Molecules. 2021;**26**(19):5784

[85] Moncada C, Repetto Y, Aldunate J, Letelier ME, Morello A. Role of glutathione in the susceptibility of *Trypanosoma cruzi* to drugs. Comparative Biochemistry and Physiology - Part C. 1989;**94**(1):87-91

[86] Repetto Y, Opazo E, Maya JD, Agosin M, Morello A. Glutathione and trypanothione in several strains of *Trypanosoma cruzi*: Effect of drugs. Comparative Biochemistry and Physiology, Part B: Biochemistry & Molecular Biology. 1996;**115**(2):281-285

[87] Mesías AC, Sasoni N, Arias DG, Pérez Brandán C, Orban OCF, Kunick C, et al. Trypanothione synthetase confers growth, survival advantage and resistance to anti-protozoal drugs in *Trypanosoma cruzi*. Free Radical Biology & Medicine. 2019;**130**:23-34

[88] Faúndez M, Pino L, Letelier P, Ortiz C, López R, Seguel C, et al. Buthionine sulfoximine increases the toxicity of nifurtimox and benznidazole to *Trypanosoma cruzi*. Antimicrobial Agents and Chemotherapy. 2005;**49**(1):126-130

[89] Faúndez M, López-Muñoz R, Torres G, Morello A, Ferreira J, Kemmerling U, et al. Buthionine

*Translational Research on Chagas Disease: Focusing on Drug Combination and Repositioning DOI: http://dx.doi.org/10.5772/intechopen.104231*

sulfoximine has anti-*Trypanosoma cruzi* activity in a murine model of acute Chagas' disease and enhances the efficacy of nifurtimox. Antimicrobial Agents and Chemotherapy. 2008;**52**(5):1837-1839

[90] Carter KC, Sundar S, Spickett C, Pereira OC, Mullen AB. The in vivo susceptibility of *Leishmania donovani* to sodium stibogluconate is drug specific and can be reversed by inhibiting glutathione biosynthesis. Antimicrobial Agents and Chemotherapy. 2003;**47**(5): 1529-1535

[91] Vannier-Santos MA, Suarez-Fontes AM. Role of polyamines in parasite cell architecture and function. Current Pharmaceutical Design. 2017;**23**(23):3342-3358

[92] Phillips MA. Polyamines in protozoan pathogens. The Journal of Biological Chemistry. 2018;**293**(48):18746-18756

[93] Hernández SM, Sánchez MS, de Tarlovsky MNS. Polyamines as a defense mechanism against lipoperoxidation in *Trypanosoma cruzi*. Acta Tropica. 2006;**98**(1):94-102

[94] Birkholtz L-M, Williams M, Niemand J, Louw AI, Persson L, Heby O. Polyamine homoeostasis as a drug target in pathogenic protozoa: Peculiarities and possibilities. The Biochemical Journal. 2011;**438**(2):229-244

[95] Roberts S, Ullman B. Parasite polyamines as pharmaceutical targets. Current Pharmaceutical Design. 2017;**23**(23):3325-3341

[96] Talevi A, Carrillo C, Comini M. The thiol-polyamine metabolism of *Trypanosoma cruzi*: Molecular targets and drug repurposing strategies. Current Medicinal Chemistry. 2019;**26**(36):6614-6635

[97] de Oliveira TB, Pedrosa RC, Filho DW. Oxidative stress in chronic cardiopathy associated with Chagas disease. International Journal of Cardiology. 2007;**116**(3):357-363

[98] Gupta S, Wen J-J, Garg NJ. Oxidative sress in Chagas disease. Interdisciplinary Perspectives on Infectious Diseases. 2009;**2009**:1-8

[99] Zacks MA, Wen J-J, Vyatkina G, Bhatia V, Garg N. An overview of chagasic cardiomyopathy: Pathogenic importance of oxidative stress. Anais da Academia Brasileira de Ciências. 2005;**77**(4):695-715

[100] Wen J, Yachelini PC, Sembaj A, Manzur RE, Garg NJ. Increased oxidative stress is correlated with mitochondrial dysfunction in chagasic patients. Free Radical Biology & Medicine. 2006;**41**(2):270-276

[101] Turrens JF. Superoxide production by the mitochondrial respiratory chain. Bioscience Reports. 1997;**17**(1):3-8

[102] Turrens JF. Mitochondrial formation of reactive oxygen species. The Journal of Physiology. 2003;**552**(2):335-344

[103] Prolo C, Estrada D, Piacenza L, Benítez D, Comini MA, Radi R, et al. Nox2-derived superoxide radical is crucial to control acute *Trypanosoma cruzi* infection. Redox Biology. 2021;**46**:102085

[104] Wen J-J, Garg N. Oxidative modification of mitochondrial respiratory complexes in response to the stress of *Trypanosoma cruzi* infection. Free Radical Biology & Medicine. 2004;**37**(12):2072-2081

[105] Dhiman M, Wan X, Popov VL, Vargas G, Garg NJ. MnSOD tg mice control myocardial inflammatory

and oxidative stress and remodeling responses elicited in chronic Chagas disease. Journal of the American Heart Association. 2013;**2**(5):e000302

[106] Maldonado E, Rojas DA, Morales S, Miralles V, Solari A. Dual and opposite roles of reactive oxygen species (ROS) in Chagas disease: Beneficial on the pathogen and harmful on the host. Oxidative Medicine and Cellular Longevity. 2020;**2020**:1-17

[107] Maldonado E, Rojas DA, Urbina F, Solari A. The oxidative stress and chronic inflammatory process in Chagas disease: Role of exosomes and contributing genetic factors. Oxidative Medicine and Cellular Longevity. 2021;**2021**:1-21

[108] Wen J-J, Vyatkina G, Garg N. Oxidative damage during chagasic cardiomyopathy development: Role of mitochondrial oxidant release and inefficient antioxidant defense. Free Radical Biology & Medicine. 2004;**37**(11):1821-1833

[109] Dantas-Pereira L, Menna-Barreto R, Lannes-Vieira J. Extracellular vesicles: Potential role in remote signaling and inflammation in Trypanosoma cruzi triggered disease. Frontiers in Cell and Development Biology. 2021;**9**:798054

[110] Chuenkova MV,

Pereiraperrin M. Neurodegeneration and neuroregeneration in Chagas disease. Advances in Parasitology. 2011;**76**:195-233

[111] Vilar-Pereira G, Castaño Barrios L, Silva AA, Martins Batista A, Resende Pereira I, Cruz Moreira O, et al. Memory impairment in chronic experimental Chagas disease: Benznidazole therapy reversed cognitive deficit in association with reduction of parasite load and oxidative stress in the nervous tissue. PLoS One. 2021;**16**(1):e0244710

[112] Wen J-J, Garg NJ. Mitochondrial generation of reactive oxygen species is enhanced at the Qo site of the complex III in the myocardium of *Trypanosoma cruzi*-infected mice: Beneficial effects of an antioxidant. Journal of Bioenergetics and Biomembranes. 2008;**40**(6):587-598

[113] Sánchez-Villamil JP, Bautista-Niño PK, Serrano NC, Rincon MY, Garg NJ. Potential role of antioxidants as adjunctive therapy in Chagas disease. Oxidative Medicine and Cellular Longevity. 2020;**2020**:1-13

[114] Du J, Cullen JJ, Buettner GR. Ascorbic acid: Chemistry, biology and the treatment of cancer. Biochimica et Biophysica Acta, Reviews on Cancer. 2012;**1826**(2):443-457

[115] Mastrangelo D, Pelosi E, Castelli G, Lo-Coco F, Testa U. Mechanisms of anticancer effects of ascorbate: Cytotoxic activity and epigenetic modulation. Blood Cells, Molecules & Diseases. 2018;**69**:57-64

[116] Puente V, Demaria A, Frank FM, Batlle A, Lombardo ME. Anti-parasitic effect of vitamin C alone and in combination with benznidazole against *Trypanosoma cruzi*. PLoS Neglected Tropical Diseases. 2018;**12**(9):e0006764

[117] Providello MV, Carneiro ZA, Portapilla GB, do Vale GT, Camargo RS, Tirapelli CR, et al. Benefits of ascorbic acid in association with low-dose benznidazole in treatment of Chagas disease. Antimicrobial Agents and Chemotherapy. 2018;**62**(9):e00514-18

[118] Piacenza L, Trujillo M, Radi R. Reactive species and pathogen antioxidant networks during phagocytosis. The Journal of Experimental Medicine. 2019;**216**(3): 501-516

*Translational Research on Chagas Disease: Focusing on Drug Combination and Repositioning DOI: http://dx.doi.org/10.5772/intechopen.104231*

[119] Piacenza L, Peluffo G, Alvarez MN, Martínez A, Radi R. *Trypanosoma cruzi* antioxidant enzymes as virulence factors in Chagas disease. Antioxidants & Redox Signaling. 2013;**19**(7):723-734

[120] Oyenihi OR, Oyenihi AB, Alabi TD, Tade OG, Adeyanju AA, Oguntibeju OO. Reactive oxygen species: Key players in the anticancer effects of apigenin? Journal of Food Biochemistry. 2022;**46**(2):e14060

[121] Goes GR, Rocha PS, Diniz ARS, Aguiar PHN, Machado CR, Vieira LQ. *Trypanosoma cruzi* needs a signal provided by reactive oxygen species to infect macrophages. PLoS Neglected Tropical Diseases. 2016;**10**(4):e0004555

[122] Paiva CN, Feijó DF, Dutra FF, Carneiro VC, Freitas GB, Alves LS, et al. Oxidative stress fuels *Trypanosoma cruzi* infection in mice. The Journal of Clinical Investigation. 2012;**122**(7):2531-2542

[123] Dumoulin PC, Burleigh BA. Stress induced proliferation and cell cycle plasticity of intracellular *Trypanosoma cruzi* amastigotes. MBio. 2018;**9**(4):e00673-18

[124] Batinić-Haberle I, Rebouças JS, Spasojević I. Redox-Active Therapeutics. 1st ed. Switzerland: Springer International Publishing; 2016. 1261 p

[125] Turrens JF. Oxidative stress and antioxidant defenses: A target for the treatment of diseases caused by parasitic protozoa. Molecular Aspects of Medicine. 2004;**25**(1-2):211-220

[126] Docampo R, Moreno SNJ. Free radical metabolites in the mode of action of chemotherapeutic agents and phagocytic cells on *Trypanosoma cruzi*. Clinical Infectious Diseases. 1984;**6**(2):223-238

[127] Beltran-Hortelano I, Perez-Silanes S, Galiano S. Trypanothione reductase

and superoxide dismutase as current drug targets for *Trypanosoma cruzi*: An overview of compounds with activity against Chagas disease. Current Medicinal Chemistry. 2017;**24**(11):1066-1138

[128] Boveris A, Docampo R, Turrens JF, Stoppani AO. Effect of β-lapachone on superoxide anion and hydrogen peroxide production in *Trypanosoma cruzi*. The Biochemical Journal. 1978;**175**(2):431-439

[129] Cruz FS, Docampo R, de Souza W. Effect of beta-lapachone on hydrogen peroxide production in *Trypanosoma cruzi*. Acta Tropica. 1978;**35**(1):35-40

[130] Docampo R, Cruz FS, Boveris A, Muniz RPA, Esquivel DMS. Lipid peroxidation and the generation of free radicals, superoxide anion, and hydrogen peroxide in β-lapachonetreated *Trypanosoma cruzi* epimastigotes. Archives of Biochemistry and Biophysics. 1978;**186**(2):292-297

[131] Bombaça ACS, Viana PG, Santos ACC, Silva TL, Rodrigues ABM, Guimarães ACR, et al. Mitochondrial disfunction and ROS production are essential for anti-*Trypanosoma cruzi* activity of β-lapachone-derived naphthoimidazoles. Free Radical Biology & Medicine. 2019;**130**:408-418

[132] Gong Q, Hu J, Wang P, Li X, Zhang X. A comprehensive review on β-lapachone: Mechanisms, structural modifications, and therapeutic potentials. European Journal of Medicinal Chemistry. 2021;**210**: 112962

[133] Menna-Barreto RFS, Henriques-Pons A, Pinto AV, Morgado-Diaz JA, Soares MJ, De Castro SL. Effect of a β-lapachonederived naphthoimidazole on *Trypanosoma cruzi*: Identification of target organelles. The Journal

of Antimicrobial Chemotherapy. 2005;**56**(6):1034-1041

[134] dos Anjos DO, Sobral Alves ES, Gonçalves VT, Fontes SS, Nogueira ML, Suarez-Fontes AM, et al. Effects of a novel β-lapachone derivative on *Trypanosoma cruzi*: Parasite death involving apoptosis, autophagy and necrosis. International Journal for Parasitology: Drugs and Drug Resistance. 2016;**6**(3):207-219

[135] Yang Y, Karakhanova S, Hartwig W, D'Haese JG, Philippov PP, Werner J, et al. Mitochondria and mitochondrial ROS in cancer: Novel targets for anticancer therapy. Journal of Cellular Physiology. 2016;**231**(12):2570-2581

[136] Dhote V, Samundre P, Ganeshpurkar A, Upaganlawar A. Aging of brain related with mitochondrial dysfunctions. Current Drug Targets. 2021;**22**(14):1668-1687

[137] Dabravolski SA, Nikiforov NG, Starodubova AV, Popkova TV, Orekhov AN. The role of mitochondriaderived peptides in cardiovascular diseases and their potential as therapeutic targets. International Journal of Molecular Sciences. 2021;**22**(16):8770

[138] Clayton SA, MacDonald L, Kurowska-Stolarska M, Clark AR. Mitochondria as key players in the pathogenesis and treatment of rheumatoid arthritis. Frontiers in Immunology. 2021;**12**:673916

[139] Sharma VK, Singh TG, Mehta V. Stressed mitochondria: A target to intrude Alzheimer's disease. Mitochondrion. 2021;**59**:48-57

[140] Fakhri S, Abdian S, Zarneshan SN, Akkol EK, Farzaei MH, Sobarzo-Sánchez E. Targeting mitochondria by plant secondary

metabolites: A promising strategy in combating Parkinson's disease. International Journal of Molecular Sciences. 2021;**22**(22):12570

[141] Kita K, Nihei C, Tomitsuka E. Parasite mitochondria as drug target: Diversity and dynamic changes during the life cycle. Current Medicinal Chemistry. 2003;**10**(23):2535-2548

[142] Monzote L, Gille L. Mitochondria as a promising antiparasitic target. Current Clinical Pharmacology. 2010;**5**(1):55-66

[143] Mather M, Henry K, Vaidya A. Mitochondrial drug targets in apicomplexan parasites. Current Drug Targets. 2007;**8**(1):49-60

[144] Sen N, Majumder H. Mitochondrion of protozoan parasite emerges as potent therapeutic target: Exciting drugs are on the horizon. Current Pharmaceutical Design. 2008;**14**(9):839-846

[145] Goodman CD, Buchanan HD, McFadden GI. Is the mitochondrion a good malaria drug target? Trends in Parasitology. 2017;**33**(3):185-193

[146] Nihei C, Fukai Y, Kita K. Trypanosome alternative oxidase as a target of chemotherapy. Biochimica et Biophysica Acta, Molecular Basis of Disease. 2002;**1587**(2-3):234-239

[147] Machado MM. Kinetoplast as a potential chemotherapeutic target of trypanosomatids. Current Pharmaceutical Design. 2008;**14**(9):847-854

[148] Fidalgo LM, Gille L. Mitochondria and trypanosomatids: Targets and drugs. Pharmaceutical Research. 2011;**28**(11):2758-2770

[149] Boveris A, Chance B. The mitochondrial generation of hydrogen *Translational Research on Chagas Disease: Focusing on Drug Combination and Repositioning DOI: http://dx.doi.org/10.5772/intechopen.104231*

peroxide. General properties and effect of hyperbaric oxygen. The Biochemical Journal. 1973;**134**(3):707-716

[150] Menna-Barreto RFS, de Castro SL. The double-edged sword in pathogenic trypanosomatids: The pivotal role of mitochondria in oxidative stress and bioenergetics. BioMed Research International. 2014;**2014**:1-14

[151] Turrens JF, McCord JM. The ironcontaining superoxide dismutases of Trypanosomatidae. Free Radical Biology & Medicine. 2006;**40**(2):193-195

[152] Martínez A, Prolo C, Estrada D, Rios N, Alvarez MN, Piñeyro MD, et al. Cytosolic Fe-superoxide dismutase safeguards *Trypanosoma cruzi* from macrophage-derived superoxide radical. Proceedings of the National Academy of Sciences. 2019;**116**(18):8879-8888

[153] Docampo R, Moreno SN. Free radical metabolism of antiparasitic agents. Federation Proceedings. 1986;**45**(10):2471-2476

[154] Docampo R. Sensitivity of parasites to free radical damage by antiparasitic drugs. Chemico-Biological Interactions. 1990;**73**(1):1-27

[155] Perbandt M, Ndjonka D, Liebau E. Protective mechanisms of Helminths against reactive oxygen species are highly promising drug targets. Current Medicinal Chemistry. 2014;**21**(15):1794-1808

[156] Pal C, Bandyopadhyay U. Redoxactive antiparasitic drugs. Antioxidants & Redox Signaling. 2012;**17**(4):555-582

[157] Piacenza L, Irigoín F, Alvarez MN, Peluffo G, Taylor MC, Kelly JM, et al. Mitochondrial superoxide radicals mediate programmed cell death in *Trypanosoma cruzi*: Cytoprotective

action of mitochondrial iron superoxide dismutase overexpression. The Biochemical Journal. 2007;**403**(2):323-334

[158] Maya JD, Cassels BK, Iturriaga-Vásquez P, Ferreira J, Faúndez M, Galanti N, et al. Mode of action of natural and synthetic drugs against *Trypanosoma cruzi* and their interaction with the mammalian host. Comparative Biochemistry and Physiology, Part A: Molecular & Integrative Physiology. 2007;**146**(4):601-620

[159] Docampo R, Mason RP, Mottley C, Muniz RP. Generation of free radicals induced by nifurtimox in mammalian tissues. The Journal of Biological Chemistry. 1981;**256**(21):10930-10933

[160] Faúndez M, Rojas M, Bohle P, Reyes C, Letelier ME, Aliaga ME, et al. Pyrogallol red oxidation induced by superoxide radicals: Application to evaluate redox cycling of nitro compounds. Analytical Biochemistry. 2011;**419**(2):284-291

[161] Moreno SNJ, Docampo R, Mason RP, Leon W, Stoppani AOM. Different behaviors of benznidazole as free radical generator with mammalian and *Trypanosoma cruzi* microsomal preparations. Archives of Biochemistry and Biophysics. 1982;**218**(2):585-591

[162] Nogueira FB, Krieger MA, Nirdé P, Goldenberg S, Romanha AJ, Murta SMF. Increased expression of iron-containing superoxide dismutase-A (TcFeSOD-A) enzyme in *Trypanosoma cruzi* population with in vitro-induced resistance to benznidazole. Acta Tropica. 2006;**100**(1-2):119-132

[163] Campos MC, Phelan J, Francisco AF, Taylor MC, Lewis MD, Pain A, et al. Genome-wide mutagenesis and multi-drug resistance in American

trypanosomes induced by the front-line drug benznidazole. Scientific Reports. 2017;**7**(1):14407

[164] Andrade HM, Murta SMF, Chapeaurouge A, Perales J, Nirdé P, Romanha AJ. Proteomic analysis of *Trypanosoma cruzi* resistance to benznidazole. Journal of Proteome Research. 2008;**7**(6):2357-2367

[165] Quebrada Palacio LP, González MN, Hernandez-Vasquez Y, Perrone AE, Parodi-Talice A, Bua J, et al. Phenotypic diversity and drug susceptibility of *Trypanosoma cruzi* TcV clinical isolates. PLoS One. 2018;**13**(9):e0203462

[166] Prathalingham SR, Wilkinson SR, Horn D, Kelly JM. Deletion of the *Trypanosoma brucei* superoxide dismutase gene sodb1 increases sensitivity to nifurtimox and benznidazole. Antimicrobial Agents and Chemotherapy. 2007;**51**(2):755-758

[167] Veronica J, Chandrasekaran S, Dayakar A, Devender M, Prajapati VK, Sundar S, et al. Iron superoxide dismutase contributes to miltefosine resistance in *Leishmania donovani*. The FEBS Journal. 2019;**286**(17):3488-3503

[168] Santi AMM, Silva PA, Santos IFM, Murta SMF. Downregulation of FeSOD-A expression in *Leishmania infantum* alters trivalent antimony and miltefosine susceptibility. Parasites & Vectors. 2021;**14**(1):366

[169] Wassmann C, Hellberg A, Tannich E, Bruchhaus I. Metronidazole resistance in the protozoan parasite *Entamoeba histolytica* is associated with increased expression of ironcontaining superoxide dismutase and peroxiredoxin and decreased expression of ferredoxin 1 and flavin reductase. The Journal of Biological Chemistry. 1999;**274**(37):26051-26056

[170] Andrade JM, Murta SMF. Functional analysis of cytosolic tryparedoxin peroxidase in antimony-resistant and -susceptible *Leishmania braziliensis* and *Leishmania infantum* lines. Parasites & Vectors. 2014;**7**(1):406

[171] Olmo F, Urbanová K, Rosales MJ, Martín-Escolano R, Sánchez-Moreno M, Marín C. An in vitro iron superoxide dismutase inhibitor decreases the parasitemia levels of *Trypanosoma cruzi* in BALB/c mouse model during acute phase. International Journal for Parasitology: Drugs and Drug Resistance. 2015;**5**(3):110-116

[172] Singh CK, Chhabra G, Ndiaye MA, Garcia-Peterson LM, Mack NJ, Ahmad N. The role of sirtuins in antioxidant and redox signaling. Antioxidants & Redox Signaling. 2018;**28**(8):643-661

[173] Klein MA, Denu JM. Biological and catalytic functions of sirtuin 6 as targets for small-molecule modulators. The Journal of Biological Chemistry. 2020;**295**(32):11021-11041

[174] Huang J-Y, Hirschey MD, Shimazu T, Ho L, Verdin E. Mitochondrial sirtuins. Biochimica et Biophysica Acta, Proteins and Proteomics. 2010;**1804**(8):1645-1651

[175] Wan X, Garg NJ. Sirtuin control of mitochondrial dysfunction, oxidative stress, and inflammation in Chagas disease models. Frontiers in Cellular and Infection Microbiology. 2021;**11**:693051

[176] Chen Y, Zhang J, Lin Y, Lei Q, Guan K, Zhao S, et al. Tumour suppressor SIRT3 deacetylates and activates manganese superoxide dismutase to scavenge ROS. EMBO Reports. 2011;**12**(6):534-541

[177] dos Santos ML, Santana Nunes V, Gomes AAS, Sousa AC de *Translational Research on Chagas Disease: Focusing on Drug Combination and Repositioning DOI: http://dx.doi.org/10.5772/intechopen.104231*

CN, Fontes MRM, Schenkman S, et al. Mitochondrial sirtuin TcSir2rp3 affects TcSODA activity and oxidative stress response in *Trypanosoma cruzi*. Frontiers in Cellular and Infection Microbiology. 2021;**11**:773410

[178] Davis CD, Brooks L, Calisi C, Bennett BJ, McElroy DM. Beneficial effect of selenium supplementation during murine infection with *Trypanosoma cruzi*. The Journal of Parasitology. 1998;**84**(6):1274-1277

[179] Gomez RM, Solana ME, Levander OA. Host selenium deficiency increases the severity of chronic inflammatory myopathy in *Trypanosoma cruzi*-inoculated mice. The Journal of Parasitology. 2002;**88**(3):541-547

[180] de Souza AP, de Oliveira GM, Vanderpas J, de Castro SL, Rivera MT, Araújo-Jorge TC. Selenium supplementation at low doses contributes to the decrease in heart damage in experimental *Trypanosoma cruzi* infection. Parasitology Research. 2003;**91**(1):51-54

[181] Holanda MT, Mediano MFF, Hasslocher-Moreno AM, Gonzaga BMS, Carvalho ACC, Ferreira RR, et al. Effects of selenium treatment on cardiac function in Chagas heart disease: Results from the STCC randomized trial. eClinicalMedicine. 2021;**40**:101105

[182] Correa-Oliveira R, Araújo-Jorge TC, Rocha MOC, Rivera MT, Nève J, Moreno AHM, et al. Progressive Chagas' cardiomyopathy is associated with low selenium levels. The American Journal of Tropical Medicine and Hygiene. 2002;**66**(6):706-712

[183] Alcolea V, Pérez-Silanes S. Selenium as an interesting option for the treatment of Chagas disease: A review. European Journal of Medicinal Chemistry. 2020;**206**:112673

[184] Maldonado E, Rojas DA, Urbina F, Solari A. The use of antioxidants as potential co-adjuvants to treat chronic Chagas disease. Antioxidants. 2021;**10**(7):1022

[185] Martín-Escolano R, Etxebeste-Mitxeltorena M, Martín-Escolano J, Plano D, Rosales MJ, Espuelas S, et al. Selenium derivatives as promising therapy for Chagas disease: In vitro and in vivo studies. ACS Infectious Diseases. 2021;**7**(6):1727-1738

[186] de Freitas MRB, da Costa CMB, Pereira LM, do Prado JC, Sala MA, Abrahão AA. The treatment with selenium increases placental parasitismin pregnant Wistar rats infected with the Y strain of *Trypanosoma cruzi*. Immunobiology. 2018;**223**(10):537-543

[187] Kim SJ, Choi MC, Park JM, Chung AS. Antitumor effects of selenium. International Journal of Molecular Sciences. 2021;**22**(21):11844

[188] Zheng Y, Xie T, Li S, Wang W, Wang Y, Cao Z, et al. Effects of selenium as a dietary source on performance, inflammation, cell damage, and reproduction of livestock induced by heat stress: A review. Frontiers in Immunology. 2022;**12**:820853

[189] Orian L, Flohé L. Seleniumcatalyzed reduction of hydroperoxides in chemistry and biology. Antioxidants. 2021;**10**(10):1560

[190] Planer JD, Hulverson MA, Arif JA, Ranade RM, Don R, Buckner FS. Synergy testing of FDA-approved drugs identifies potent drug combinations against *Trypanosoma cruzi*. PLoS Neglected Tropical Diseases. 2014;**8**(7):e2977

[191] Kaiser M, Mäser P, Tadoori LP, Ioset J-R, Brun R. Antiprotozoal activity profiling of approved drugs: A starting point toward drug repositioning. PLoS One. 2015;**10**(8):e0135556

[192] Lehár J, Krueger AS, Avery W, Heilbut AM, Johansen LM, Price ER, et al. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nature Biotechnology. 2009;**27**(7):659-666

[193] Lehar J, Krueger AS, Zimmermann GR, Borisy AA. Therapeutic selectivity and the multi-node drug target. Discovery Medicine. 2009;**8**(43):185-190

[194] Zimmermann GR, Lehár J, Keith CT. Multi-target therapeutics: When the whole is greater than the sum of the parts. Drug Discovery Today. 2007;**12**(1-2):34-42

[195] Borisy AA, Elliott PJ, Hurst NW, Lee MS, Lehar J, Price ER, et al. Systematic discovery of multicomponent therapeutics. Proceedings of the National Academy of Sciences. 2003;**100**(13):7977-7982

[196] Kabir A, Muth A. Polypharmacology: The science of multitargeting molecules. Pharmacological Research. 2022;**176**:106055

[197] Aguilera E, Alvarez G, Cerecetto H, González M. Polypharmacology in the treatment of Chagas disease. Current Medicinal Chemistry. 2019;**26**(23):4476-4489

[198] Mitchison DA. Prevention of drug resistance by combined drug treatment of tuberculosis. In: Coates, A, editor. Antibiotic Resistance. Handbook of Experimental Pharmacology. Springer, Berlin, Heidelberg. 2012;**211**:87-98

[199] Worthington RJ, Melander C. Combination approaches to combat multidrug-resistant bacteria. Trends in Biotechnology. 2013;**31**(3):177-184

[200] Hill JA, Cowen LE. Using combination therapy to thwart drug resistance. Future Microbiology. 2015;**10**(11):1719-1726

[201] Yadav B, Wennerberg K, Aittokallio T, Tang J. Searching for drug synergy in complex dose–response landscapes using an interaction potency model. Computational and Structural Biotechnology Journal. 2015;**13**:504-513

[202] Singh N, Yeh PJ. Suppressive drug combinations and their potential to combat antibiotic resistance. Journal of Antibiotics (Tokyo). 2017;**70**(11):1033-1042

[203] Wani M, Ahmad A. Combination Therapy Against Multidrug Resistance. 1st ed. London: Elsevier, Academic Press; 2020. 260 p

[204] Liu Y, Tong Z, Shi J, Li R, Upton M, Wang Z. Drug repurposing for nextgeneration combination therapies against multidrug-resistant bacteria. Theranostics. 2021;**11**(10):4910-4928

[205] Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR. Epidemiology of drugresistant malaria. The Lancet Infectious Diseases. 2002;**2**(4):209-218

[206] Tu Y. From *Artemisia annua* L. to Artemisinins the Discovery and Development of Artemisinins and Antimalarial Agents. 1st ed. London: Agents Academic Press; 2017. 468 p

[207] Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of Artemisinin resistance in *Plasmodium falciparum* malaria. The New England Journal of Medicine. 2014;**371**(5):411-423

[208] Eastman RT, Fidock DA. Artemisinin-based combination *Translational Research on Chagas Disease: Focusing on Drug Combination and Repositioning DOI: http://dx.doi.org/10.5772/intechopen.104231*

therapies: A vital tool in efforts to eliminate malaria. Nature Reviews. Microbiology. 2009;**7**(12):864-874

[209] Rogers WO, Sem R, Tero T, Chim P, Lim P, Muth S, et al. Failure of artesunate-mefloquine combination therapy for uncomplicated *Plasmodium falciparum* malaria in Southern Cambodia. Malaria Journal. 2009;**8**(1):10

[210] Lim P, Alker AP, Khim N, Shah NK, Incardona S, Doung S, et al. Pfmdr1 copy number and arteminisin derivatives combination therapy failure in falciparum malaria in Cambodia. Malaria Journal. 2009;**8**(1):11

[211] Alker AP, Lim P, Sem R, Shah NK, Yi P, Bouth DM, et al. Pfmdr1 and in vivo resistance to artesunate-mefloquine in falciparum malaria on the Cambodian-Thai border. The American Journal of Tropical Medicine and Hygiene. 2007;**76**(4):641-647

[212] Nosengo N. Can you teach old drugs new tricks? Nature. 2016;**534**(7607):314-316

[213] Xue H, Li J, Xie H, Wang Y. Review of drug repositioning approaches and resources. International Journal of Biological Sciences. 2018;**14**(10):1232-1244

[214] Simões-Silva MR, De Araújo JS, Peres RB, Da Silva PB, Batista MM, De Azevedo LD, et al. Repurposing strategies for Chagas disease therapy: The effect of imatinib and derivatives against *Trypanosoma cruzi*. Parasitology. 2019;**146**(8):1006-1012

[215] Juárez-Saldivar A, Schroeder M, Salentin S, Haupt VJ, Saavedra E, Vázquez C, et al. Computational drug repositioning for Chagas disease using protein-ligand interaction profiling. International

Journal of Molecular Sciences. 2020;**21**(12):4270

[216] Trindade JDS, Freire-de-Lima CG, Côrte-Real S, Decote-Ricardo D, Freire de Lima ME. Drug repurposing for Chagas disease: In vitro assessment of nimesulide against *Trypanosoma cruzi* and insights on its mechanisms of action. PLoS One. 2021;**16**(10):e0258292

[217] Martinez-Peinado N, Cortes-Serra N, Sherman J, Rodriguez A, Bustamante JM, Gascon J, et al. Identification of *Trypanosoma cruzi* growth inhibitors with activity in vivo within a collection of licensed drugs. Microorganisms. 2021;**9**(2):406

[218] Rivero CV, Martínez SJ, Novick P, Cueto JA, Salassa BN, Vanrell MC, et al. Repurposing Carvedilol as a novel inhibitor of the *Trypanosoma cruzi* autophagy flux that affects parasite replication and survival. Frontiers in Cellular and Infection Microbiology. 2021;**11**:657257

[219] Valsecchi WM, Delfino JM, Santos J, Fernández Villamil SH. Zoledronate repositioning as a potential trypanocidal drug. *Trypanosoma cruzi* HPRT an alternative target to be considered. Biochemical Pharmacology. 2021;**188**:114524

[220] Bellera CL, Alberca LN, Sbaraglini ML, Talevi A. In silico drug repositioning for Chagas disease. Current Medicinal Chemistry. 2020;**27**(5):662-675

[221] Reigada C, Sayé M, Phanstiel O, Valera-Vera E, Miranda MR, Pereira CA. Identification of *Trypanosoma cruzi* polyamine transport inhibitors by computational drug repurposing. Frontiers in Medicine. 2019;**6**:256

[222] Valera-Vera EA, Sayé M, Reigada C, Miranda MR, Pereira CA. In silico repositioning of etidronate as a potential inhibitor of the *Trypanosoma cruzi* enolase. Journal of Molecular Graphics & Modelling. 2020;**95**: 107506

[223] Miranda MR, Sayé MM. Chagas disease treatment: From new therapeutic targets to drug discovery and repositioning. Current Medicinal Chemistry. 2019;**26**(36):6517-6518

[224] Santos SS, de Araújo RV, Giarolla J, Seoud O El, Ferreira EI. Searching for drugs for Chagas disease, leishmaniasis and schistosomiasis: A review. International Journal of Antimicrobial Agents 2020;55(4):105906.

[225] Adasme MF, Bolz SN, Adelmann L, Salentin S, Haupt VJ, Moreno-Rodríguez A, et al. Repositioned drugs for Chagas disease unveiled via structure-based drug repositioning. International Journal of Molecular Sciences. 2020;**21**(22):8809

[226] Martínez-Flórez A, Galizzi M, Izquierdo L, Bustamante JM, Rodriguez A, Rodriguez F, et al. Repurposing bioenergetic modulators against protozoan parasites responsible for tropical diseases. International Journal for Parasitology: Drugs and Drug Resistance. 2020;**14**:17-27

[227] Benaim G, Paniz-Mondolfi AE, Sordillo EM. The rationale for use of amiodarone and its derivatives for the treatment of Chagas' disease and Leishmaniasis. Current Pharmaceutical Design. 2021;**27**(15):1825-1833

[228] Zuma AA, de Souza W. Chagas disease chemotherapy: What do we know so far? Current Pharmaceutical Design. 2021;**27**(38):3963-3995

[229] Torrico F, Gascón J, Barreira F, Blum B, Almeida IC, Alonso-Vega C, et al. New regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BENDITA): A phase 2, double-blind, randomised trial. The Lancet Infectious Diseases. 2021;**21**(8):1129-1140

[230] Mazzeti AL, Gonçalves KR, Mota SLA, Pereira DE, Diniz L, Bahia MT. Combination therapy using nitro compounds improves the efficacy of experimental Chagas disease treatment. Parasitology. 2021;**148**(11):1320-1327

[231] Mazzeti AL, Capelari-Oliveira P, Bahia MT, Mosqueira VCF. Review on experimental treatment strategies against *Trypanosoma cruzi*. Journal of Experimental Pharmacology. 2021;**13**:409-432

[232] Peerzada MN, Gaur A, Azam A. Advances in drug discovery against neglected tropical diseases: Human African and American Trypanosomiasis. Current Medicinal Chemistry. 2021;**28**(36):7544-7582

[233] Ferraz LRM, Silva LC, de Souza ML, Alves LP, de Sales V, Barbosa NG, et al. Drug associations as alternative and complementary therapy for neglected tropical diseases. Acta Tropica. 2022;**225**:106210

[234] Araujo-Lima CF, Peres RB, Silva PB, Batista MM, Aiub CAF, Felzenszwalb I, et al. Repurposing strategy of atorvastatin against *Trypanosoma cruzi*: In vitro monotherapy and combined therapy with benznidazole exhibit synergistic trypanocidal activity. Antimicrobial Agents and Chemotherapy. 2018;**62**(9):e00979-18

[235] Sass G, Madigan RT, Joubert L-M, Bozzi A, Sayed N, Wu JC, et al. A combination of itraconazole and amiodarone is highly effective against *Translational Research on Chagas Disease: Focusing on Drug Combination and Repositioning DOI: http://dx.doi.org/10.5772/intechopen.104231*

*Trypanosoma cruzi* infection of human stem cell-derived cardiomyocytes. The American Journal of Tropical Medicine and Hygiene. 2019;**101**(2):383-391

[236] Simões-Silva MR, De Araújo JS, Oliveira GM, Demarque KC, Peres RB, D'Almeida-Melo I, et al. Drug repurposing strategy against *Trypanosoma cruzi* infection: In vitro and in vivo assessment of the activity of metronidazole in monoand combined therapy. Biochemical Pharmacology. 2017;**145**:46-53

[237] Sun W, Sanderson PE, Zheng W. Drug combination therapy increases successful drug repositioning. Drug Discovery Today. 2016;**21**(7):1189-1195

[238] Pandey RP, Nascimento MS, Moore CE, Raj VS, Kalil J, Cunha-Neto E. New approaches for the treatment of Chagas disease. Current Drug Targets. 2021;**22**(7):835-841

[239] Sousa A. Disulfiram: Its Use in Alcohol Dependence and Other Disorders. 1 st ed. Singapore: Springer; 2019. 133 p

[240] Suh JJ, Pettinati HM, Kampman KM, O'Brien CP. The status of disulfiram. Journal of Clinical Psychopharmacology. 2006;**26**(3):290-302

[241] Bala V, Gupta G, Sharma V. Chemical and medicinal versatility of dithiocarbamates: An overview. Mini Reviews in Medicinal Chemistry. 2014;**14**(12):1021-1032

[242] Shinde SD, Sakla AP, Shankaraiah N. An insight into medicinal attributes of dithiocarbamates: Bird's eye view. Bioorganic Chemistry. 2020;**105**:104346

[243] Gessner PK, Gessner T. Disulfiram and Its Metabolite, Diethyldithiocarbamate. Dordrecht: Springer Netherlands; 1992

[244] Rath NC, Rasaputra KS, Liyanage R, Huff GR and Huff WE. Dithiocarbamate Toxicity - An Appraisal. In: Stoytcheva M, editor. Pesticides in the Modern World - Effects of Pesticides Exposure. London, UK: InTechOpen; 2011. pp. 323-340

[245] Hald J, Jacobsen E. A drug sensitising the organism to ethyl alcohol. Lancet. 1948;**252**(6539):1001-1004

[246] Lu C, Li X, Ren Y, Zhang X. Disulfiram: A novel repurposed drug for cancer therapy. Cancer Chemotherapy and Pharmacology. 2021;**87**(2):159-172

[247] Jia Y, Huang T. Overview of Antabuse® (Disulfiram) in radiation and cancer biology. Cancer Management and Research. 2021;**13**:4095-4101

[248] Meraz-Torres F, Plöger S, Garbe C, Niessner H, Sinnberg T. Disulfiram as a therapeutic agent for metastatic malignant melanoma—Old myth or new logos? Cancers (Basel). 2020;**12**(12):3538

[249] Jiao Y, Hannafon BN, Ding W-Q. Disulfiram's anticancer activity: Evidence and mechanisms. Anti-Cancer Agents in Medicinal Chemistry. 2016;**16**(11):1378-1384

[250] Spivak AM, Planelles V. Novel latency reversal agents for HIV-1 cure. Annual Review of Medicine. 2018;**69**(1):421-436

[251] de Moura FB, Kohut SJ, Bergman J. Limited modulation of the abuse-related behavioral effects of d-methamphetamine by disulfiram. Experimental and Clinical Psychopharmacology. 2018;**26**(5):497-502

[252] Reinhardt S, Stoye N, Luderer M, Kiefer F, Schmitt U, Lieb K, et al. Identification of disulfiram as a secretase-modulating compound with beneficial effects on Alzheimer's

disease hallmarks. Scientific Reports. 2018;**8**(1):1329

[253] Gao J, Gong Z, Montesano D, Glazer E, Liegner K. "Repurposing" disulfiram in the treatment of lyme disease and babesiosis: Retrospective review of first 3 years' experience in one medical practice. Antibiotics. 2020;**9**(12):868

[254] Zitko J, Doležal M. Old drugs and new targets as an outlook for the treatment of tuberculosis. Current Medicinal Chemistry. 2019;**25**(38):5142-5167

[255] Das S, Garg T, Chopra S, Dasgupta A. Repurposing disulfiram to target infections caused by nontuberculous mycobacteria. The Journal of Antimicrobial Chemotherapy. 2019;**74**(5):1317-1322

[256] Castillo-Villanueva A, Rufino-González Y, Méndez S-T, Torres-Arroyo A, Ponce-Macotela M, Martínez-Gordillo MN, et al. Disulfiram as a novel inactivator of *Giardia lamblia* triosephosphate isomerase with antigiardial potential. International Journal for Parasitology: Drugs and Drug Resistance. 2017;**7**(3):425-432

[257] Shirley D-A, Sharma I, Warren CA, Moonah S. Drug repurposing of the alcohol abuse medication disulfiram as an anti-parasitic agent. Frontiers in Cellular and Infection Microbiology. 2021;**11**:633194

[258] Omran Z, Sheikh R, Baothman OA, Zamzami MA, Alarjah M. Repurposing disulfiram as an anti-obesity drug: Treating and preventing obesity in high-fat-fed rats. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2020;**13**:1473-1480

[259] Kannappan V, Ali M, Small B, Rajendran G, Elzhenni S, Taj H, et al. Recent advances in repurposing disulfiram and disulfiram derivatives as copperdependent anticancer agents. Frontiers in Molecular Biosciences. 2021;**8**:741316

[260] Fong W, To KK. Drug repurposing to overcome resistance to various therapies for colorectal cancer. Cellular and Molecular Life Sciences. 2019;**76**(17):3383-3406

[261] Ekinci E, Rohondia S, Khan R, Dou QP. Repurposing disulfiram as an anti-cancer agent: Updated review on literature and patents. Recent Patents on Anti-Cancer Drug Discovery. 2019;**14**(2):113-132

[262] Horita Y, Takii T, Yagi T, Ogawa K, Fujiwara N, Inagaki E, et al. Antitubercular activity of disulfiram, an antialcoholism drug, against multidrug- and extensively drugresistant mycobacterium tuberculosis isolates. Antimicrobial Agents and Chemotherapy. 2012;**56**(8):4140-4145

[263] Long TE. Repurposing thiram and disulfiram as antibacterial agents for *multidrug-resistant Staphylococcus aureus* infections. Antimicrobial Agents and Chemotherapy. 2017;**61**(9):e00898-17

[264] Sauna ZE, Shukla S, Ambudkar SV. Disulfiram, an old drug with new potential therapeutic uses for human cancers and fungal infections. Molecular BioSystems. 2005;**1**(2):127

[265] Argüello-García R, Leitsch D, Skinner-Adams T, Ortega-Pierres MG. Drug resistance in Giardia: Mechanisms and alternative treatments for Giardiasis. Advances in Parasitology. 2020;**107**:201-282

[266] Cvek B. Nonprofit drugs as the salvation of the world's healthcare

*Translational Research on Chagas Disease: Focusing on Drug Combination and Repositioning DOI: http://dx.doi.org/10.5772/intechopen.104231*

systems: The case of Antabuse (disulfiram). Drug Discovery Today. 2012;**17**(9-10):409-412

[267] Jørgensen CH, Pedersen B, Tønnesen H. The efficacy of disulfiram for the treatment of alcohol use disorder. Alcoholism, Clinical and Experimental Research. 2011;**35**(10):1749-1758

[268] Sinclair JMA, Chambers SE, Shiles CJ, Baldwin DS. Safety and tolerability of pharmacological treatment of alcohol dependence: Comprehensive review of evidence. Drug Safety. 2016;**39**(7):627-645

[269] Reisinger EC, Kern P, Dietrich M, Ernst M, Flad HD, Bock P, et al. Inhibition of HIV progression by dithiocarb. Lancet. 1990;**335**(8691):679- 682

[270] Pompidou A, Delsaux MC, Telvi L, Mace B, Coutance F, Falkenrodt A, et al. Isoprinosine and Imuthiol, two potentially active compounds in patients with AIDS-related complex symptoms. Cancer Research. 1985;**45**(9):4671-4673

[271] Lemarie E, Musset M, Charbonnier C, Renoux M, Renoux G. Clinical characterization of imuthiol. Methods and Findings in Experimental and Clinical Pharmacology. 1986;**8**(1):51-54

[272] Khouri R, Novais F, Santana G, de Oliveira CI, Vannier dos Santos MA, Barral A, et al. DETC induces leishmania parasite killing in human in vitro and murine in vivo models: A promising therapeutic alternative in leishmaniasis. PLoS One. 2010;**5**(12):e14394

[273] Assolini JP, Tomiotto-Pellissier F, da Silva Bortoleti BT, Gonçalves MD, Sahd CS, Carloto ACM, et al. Diethyldithiocarbamate encapsulation reduces toxicity and

promotes leishmanicidal effect through apoptosis-like mechanism in promastigote and ROS production by macrophage. Journal of Drug Targeting. 2020;**28**(10):1110-1123

[274] Mazur KL, Feuser PE, Valério A, Poester Cordeiro A, de Oliveira CI, Assolini JP, et al. Diethyldithiocarbamate loaded in beeswax-copaiba oil nanoparticles obtained by solventless double emulsion technique promote promastigote death in vitro. Colloids and Surfaces. B, Biointerfaces. 2019;**176**:507-512

[275] Celes FS, Trovatti E, Khouri R, Van Weyenbergh J, Ribeiro SJL, Borges VM, et al. DETC-based bacterial cellulose bio-curatives for topical treatment of cutaneous leishmaniasis. Scientific Reports. 2016;**6**(1):38330

[276] McMahon A, Chen W, Li F. Old wine in new bottles: Advanced drug delivery systems for disulfiram-based cancer therapy. Journal of Controlled Release. 2020;**319**:352-359

[277] Kyle ME, Serroni A, Farber JL. The inhibition of lipid peroxidation by disulfiram prevents the killing of cultured hepatocytes by allyl alcohol, tert-butyl hydroperoxide, hydrogen peroxide and diethyl maleate. Chemico-Biological Interactions. 1989;**72**(3):269-275

[278] Liu T, Wang P, Cong M, Zhao X, Zhang D, Xu H, et al. Diethyldithiocarbamate, an anti-abuse drug, alleviates steatohepatitis and fibrosis in rodents through modulating lipid metabolism and oxidative stress. British Journal of Pharmacology. 2018;**175**(24):4480-4495

[279] Sundar S, Chakravarty J, Meena LP. Leishmaniasis: Treatment, drug resistance and emerging therapies. Expert Opinion on Orphan Drugs. 2019;**7**(1):1-10

[280] Calle LM, Sullivan PD. Screening of antioxidants and other compounds for antimutagenic properties towards benzo[a]pyrene-induced mutagenicity in strain TA98 of *Salmonella typhimurium*. Mutation Research. 1982;**101**(2):99-114

[281] Lane JE, Ribeiro-Rodrigues R, Suarez CC, Bogitsh BJ, Jones MM, Singh PK, et al. In vitro trypanocidal activity of tetraethylthiuram disulfide and sodium diethylamine-N-carbodithioate on *Trypanosoma cruzi*. The American Journal of Tropical Medicine and Hygiene. 1996;**55**(3):263-266

[282] de Freitas Oliveira JW, Torres TM, Moreno CJG, Amorim-Carmo B, Damasceno IZ, Soares AKMC, et al. Insights of antiparasitic activity of sodium diethyldithiocarbamate against different strains of *Trypanosoma cruzi*. Scientific Reports. 2021;**11**(1):11200

[283] Giulivi C, Turrens JF, Boveris A. Chemiluminescence enhancement by trypanocidal drugs and by inhibitors of antioxidant enzymes in *Trypanosoma cruzi*. Molecular and Biochemical Parasitology. 1988;**30**(3):243-251

[284] Koto KS, Lescault P, Brard L, Kim K, Singh RK, Bond J, et al. Antitumor activity of nifurtimox is enhanced with tetrathiomolybdate in medulloblastoma. International Journal of Oncology. 2011;**38**(5):1329-1341

[285] Prentice H, Modi JP, Wu J-Y. Mechanisms of neuronal protection against excitotoxicity, endoplasmic reticulum stress, and mitochondrial dysfunction in stroke and neurodegenerative diseases. Oxidative Medicine and Cellular Longevity. 2015;**2015**:1-7

[286] Masuda Y, Nakayama N. Protective action of diethyldithiocarbamate and carbon disulfide against renal injury induced by chloroform in mice. Biochemical Pharmacology. 1983;**32**(21):3127-3135

[287] Gandhi NM, Gopalaswamy UV, Nair CKK. Radiation protection by disulfiram: Protection of membrane and DNA in vitro and in vivo against γ-radiation. Journal of Radiation Research. 2003;**44**(3):255-259

[288] Gandhi NM, Nair CKK. Radiation protection by diethyldithiocarbamate: Protection of membrane and DNA in vitro and in vivo against γ-radiation. Journal of Radiation Research. 2004;**45**(2):175-180

[289] Wysor MS, Zwelling LA, Sanders JE, Grenan MM. Cure of mice infected with *Trypanosoma rhodesiense* by cis-diamminedichloroplatinum (ii) and disulfiram rescue. Science 80. 1982;**217**(4558):454-456

[290] Ishikawa M, Aoki T, Yomogida S, Takayanagi Y, Sasaki K. Drug interaction effects on antitumour drugs (XV): Disulfiram as protective agent against cyclophosphamideinduced urotoxicity without compromising antitumour activity in mice. Pharmacology & Toxicology. 1994;**74**(6):255-261

[291] Ishikawa M, Takayanagi Y, Sasaki K. Inhibition of ifosfamideinduced urotoxicity by disulfiram in mice. Japanese Journal of Pharmacology. 1989;**49**(1):147-150

[292] Brambilla G, Carlo P, Finollo R. Effect of ten thiocompounds on rat liver DNA damage induced by a small dose of N-nitrosodimethylamine. Archives of Toxicology. 1992;**66**(4):286-290

*Translational Research on Chagas Disease: Focusing on Drug Combination and Repositioning DOI: http://dx.doi.org/10.5772/intechopen.104231*

[293] Burman WJ, Terra M, Breese P, Cohn D, Reves R. Lack of toxicity from concomitant directly observed disulfiram and isoniazid-containing therapy for active tuberculosis. The International Journal of Tuberculosis and Lung Disease. 2002;**6**(9):839-842

[294] Traiger GJ, Vyas KP, Hanzlik RP. Effect of thiocarbonyl compounds on α-naphthylisothiocyanate-induced hepatotoxicity and the urinary excretion of [35S]α-naphthylisothiocyanate in the rat. Toxicology and Applied Pharmacology. 1984;**72**(3):504-512

[295] Hazai E, Vereczkey L, Monostory K. Reduction of toxic metabolite formation of acetaminophen. Biochemical and Biophysical Research Communications. 2002;**291**(4):1089-1094

[296] Kim HL, Jones LP. Protective effects of butylated hydroxyanisole, ethoxyquin, and disulfiram on acute pyrrolizidine alkaloids poisoning in mice. Research Communications in Chemical Pathology and Pharmacology. 1982;**36**(2):341-344

[297] Masukawa T, Nakanishi K. Protection by disulfiram and diethyldithiocarbamate against hypoxia-induced lethality in mice. Japanese Journal of Pharmacology. 1993;**63**(3):279-284

[298] Jennische E, Hansson H. Disulfiram is protective against postischemic cell death in the liver. Acta Physiologica Scandinavica. 1984;**122**(2):199-201

[299] Llobet JM, Domingo JL, Paternain JL, Corbella J. Treatment of acute lead intoxication. A quantitative comparison of a number of chelating agents. Archives of Environmental Contamination and Toxicology. 1990;**19**(2):185-189

[300] Hiroshige Ono Takayuki Funakoshi H. Comparative effects of disulfiram and diethyldithiocarbamate against testicular toxicity in rats caused by acute exposure to cadmium. Journal of Toxicology and Environmental Health. 1997;**50**(4):389-400

[301] Pages A, Casaş JS, Sanchez A, Sordo J, Bravo J, Gayoso M. Dithiocarbamates in heavy metal poisoning: Complexes of N,N-di(2 hidroxyethyl)dithiocarbamate with Zn(II), Cd(II), Hg(II), CH3Hg(II), and C6H5Hg(II). Journal of Inorganic Biochemistry. 1985;**25**(1):35-42

[302] Cohen G, Heikkila RE, Allis B, Cabbat F, Dembiec D, MacNamee D, et al. Destruction of sympathetic nerve terminals by 6-hydroxydopamine: Protection by 1-phenyl-3-(2-thiazolyl)- 2-thiourea, diethyldithiocarbamate, methimazole, cysteamine, ethanol and n-butanol. The Journal of Pharmacology and Experimental Therapeutics. 1976;**199**(2):336-352

[303] Sonawane VK, Mahajan UB, Shinde SD, Chatterjee S, Chaudhari SS, Bhangale HA, et al. A chemosensitizer drug: Disulfiram prevents doxorubicininduced cardiac dysfunction and oxidative stress in rats. Cardiovascular Toxicology. 2018;**18**(5):459-470

[304] Kis A, Yellon DM, Baxter GF. Role of nuclear factor-κB activation in acute ischaemia-reperfusion injury in myocardium. British Journal of Pharmacology. 2003;**138**(5):894-900

[305] McPherson BC, Yao Z. Signal transduction of opioid-induced cardioprotection in ischemiareperfusion. Anesthesiology. 2001;**94**(6):1082-1088

[306] Wei S, Xiao Z, Huang J, Peng Z, Zhang B, Li W. Disulfiram inhibits oxidative stress and NLRP3 inflammasome activation to prevent LPS-induced cardiac injury. International Immunopharmacology. 2022;**105**:108545

[307] Köksoy FN, Köse H, Soybír GR, Yalçin O, Cokneşelí B. The prophylactic effects of superoxide dismutase, catalase, desferrioxamine, verapamil and disulfiram in experimental colitis. Journal of the Royal College of Surgeons of Edinburgh. 1997;**42**(1):27-30

[308] Campos MCO, Castro-Pinto DB, Ribeiro GA, Berredo-Pinho MM, Gomes LHF, da Silva Bellieny MS, et al. P-glycoprotein efflux pump plays an important role in *Trypanosoma cruzi* drug resistance. Parasitology Research. 2013;**112**(6):2341-2351

[309] Loo TW, Bartlett MC, Clarke DM. Disulfiram metabolites permanently inactivate the human multidrug resistance P-glycoprotein. Molecular Pharmaceutics. 2004;**1**(6):426-433

[310] Sauna ZE, Peng X-H, Nandigama K, Tekle S, Ambudkar SV. The molecular basis of the action of disulfiram as a modulator of the multidrug resistance-linked ATP binding cassette transporters MDR1 (ABCB1) and MRP1 (ABCC1). Molecular Pharmacology. 2004;**65**(3):675-684

[311] da Costa KM, Valente RC, Salustiano EJ, Gentile LB, Freirede-Lima L, Mendonça-Previato L, et al. Functional characterization of ABCC proteins from *Trypanosoma cruzi* and their involvement with thiol transport. Frontiers in Microbiology. 2018;**9**:205

[312] Jin L, Davis MR, Hu P, Baillie TA. Identification of novel glutathione conjugates of disulfiram and diethyldithiocarbamate in rat bile by liquid chromatography-tandem

mass spectrometry. Evidence for metabolic activation of disulfiram in vivo. Chemical Research in Toxicology. 1994;**7**(4):526-533

[313] Giustarini D, Galvagni F, Tesei A, Farolfi A, Zanoni M, Pignatta S, et al. Glutathione, glutathione disulfide, and S-glutathionylated proteins in cell cultures. Free Radical Biology & Medicine. 2015;**89**:972-981

[314] Arnelle DR, Day BJ, Stamler JS. Diethyl dithiocarbamate-induced decomposition of S-Nitrosothiols. Nitric Oxide. 1997;**1**(1):56-64

[315] Johnston CD. The in vitro reaction between tetraethylthiuram disulfide (antabuse) and glutathione. Archives of Biochemistry and Biophysics. 1953;**44**(1):249-251

[316] Goldstein BD, Rozen MG, Quintavalla JC, Amoruso MA. Decrease in mouse lung and liver glutathione peroxidase activity and potentiation of the lethal effects of ozone and paraquat by the superoxide dismutase inhibitor diethyldithio-carbamate. Biochemical Pharmacology. 1979;**28**(1):27-30

[317] Kona R, Buac D, Burger M. Disulfiram, and disulfiram derivatives as novel potential anticancer drugs targeting the ubiquitin proteasome system in both preclinical and clinical studies. Current Cancer Drug Targets. 2011;**11**(3):338-346

[318] Gupta I, Aggarwal S, Singh K, Yadav A, Khan S. Ubiquitin proteasome pathway proteins as potential drug targets in parasite *Trypanosoma cruzi*. Scientific Reports. 2018;**8**(1):8399

[319] Banerjee ER. Perspectives in Translational Research in Life Sciences and Biomedicine. Springer Singapore: Singapore; 2016

*Translational Research on Chagas Disease: Focusing on Drug Combination and Repositioning DOI: http://dx.doi.org/10.5772/intechopen.104231*

[320] Saraiva RM, Portela LF, Silveira GPE da, da Gomes NL, Pinto DP, de Silva AC, et al. Disulfiram repurposing in the combined chemotherapy of Chagas disease. Medicine: Case Reports and Study Protocols. 2021;**2**(7):e0110
